Research programme: osteoporosis therapies - Transition TherapeuticsAlternative Names: BCA-902
Latest Information Update: 24 Aug 2010
At a glance
- Originator Transition Therapeutics
- Mechanism of Action Undefined mechanism
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Osteoporosis
Most Recent Events
- 15 Mar 2006 Preclinical trials in Osteoporosis in Canada (unspecified route)